Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial

BACKGROUND: Respiratory failure in severe coronavirus disease 2019 (COVID-19) is associated with a severe inflammatory response. Acetylcholine (ACh) reduces systemic inflammation in experimental bacterial and viral infections. Pyridostigmine increases the half-life of endogenous ACh, potentially red...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoso-Saavedra, Sergio, Núñez, Isaac, Audelo-Cruz, Belem M., Arias-Martínez, Sarahi, Manzur-Sandoval, Daniel, Quintero-Villegas, Alejandro, Benjamín García-González, H., Carbajal-Morelos, Sergio L., PoncedeLeón-Rosales, Sergio, Gotés-Palazuelos, José, Maza-Larrea, José A., Rosales-de la Rosa, J. Javier, Diaz-Rivera, Dafne, Luna-García, Edgar, Piten-Isidro, Elvira, Del Río-Estrada, Perla M., Fragoso-Saavedra, Mario, Caro-Vega, Yanink, Batina, Isabella, Islas-Weinstein, León, Iruegas-Nunez, David A., Calva, Juan J., Belaunzarán-Zamudio, Pablo F., Sierra-Madero, Juan, Crispín, José C., Valdés-Ferrer, Sergio Iván
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644007/
https://www.ncbi.nlm.nih.gov/pubmed/36348276
http://dx.doi.org/10.1186/s10020-022-00553-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644007/
https://www.ncbi.nlm.nih.gov/pubmed/36348276
http://dx.doi.org/10.1186/s10020-022-00553-x

Ejemplares similares